Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- MHLW Council to Discuss Otsuka’s Nalmefene for Treatment of Alcohol Dependency on Nov. 9
October 29, 2018
- ViiV’s HIV Med Juluca Up for MHLW Panel Review on Nov. 8
October 26, 2018
- MHLW to Map Out Additional Step against Rubella Outbreak by Year-End
October 25, 2018
- MHLW Warns against Advertising Claims Suggesting that OTC Cinnamon Bark Products Can Cure Diabetes
October 25, 2018
- AMED Selects 10 More Projects for CiCLE Grant Program, 4 for New Program to Support Startups
October 24, 2018
- MHLW Orders Label Revisions for Lamotrigine to Include Hemophagocytic Syndrome in ADR List
October 24, 2018
- 70% of Wholesalers Have Received Returns of “Opened and Resealed” Drugs: MHLW Survey
October 22, 2018
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme
October 19, 2018
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications
October 19, 2018
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan
October 19, 2018
- Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress
October 19, 2018
- Chuikyo Wary on CEA Use for Reimbursement Decisions as MHLW Sorts Out Discussion Points towards Full Rollout
October 18, 2018
- 3 Pharma Groups Warn against Drug Price Cut in April 2019: Chuikyo
October 18, 2018
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients
October 17, 2018
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW
October 17, 2018
- As Abe Vows to Deliver on Tax Hike Plan, 3 Pharma Groups to Push for October 2019 Price Revision
October 16, 2018
- MEXT Kicks Off “Open Innovation Organization” Initiative, 3 Universities to Push Drug Discovery
October 15, 2018
- Nobel Laurate Honjo Prods Minister on Industry Consolidation
October 12, 2018
- MHLW Panelists Frown on Use of Economic Evaluations for Reimbursement Decisions
October 11, 2018
- MOF Reiterates Drug Cost Optimization, but Makes No Fresh Proposal: Fiscal System Council
October 10, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…